Evidence map›Paper›PMID 38517188›Full record

ArticleAntimicrobial agents and chemotherapy2024

Clinical and genomic characteristics of IMP-producing

Daisuke Suzuki, Aki Sakurai, Mitsutaka Wakuda, Masahiro Suzuki, Yohei Doi

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. High-risk clonal expansion of IMP-producingAntimicrobial agents and chemotherapy · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Daisuke SuzukiDepartment of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.ORCID 0009-0002-5162-0659
Aki SakuraiDepartment of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.ORCID 0000-0003-2198-8954
Mitsutaka WakudaDepartment of Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Japan.
Masahiro SuzukiDepartment of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.ORCID 0000-0003-4550-3499
Yohei DoiDepartment of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.ORCID 0000-0002-9620-2525
Fujita Health University · JPFujita Health University Hospital · JP

Funding

Colistin-resistant Acinetobacter baumanniiR01AI104895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI, ERNST, ROBERT K · 2014 to 2024
$4.2M
Mechanisms of cefiderocol resistanceR21AI151362 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2020 to 2021
$420k
NIAID NIH HHS R01 AI104895NIAID NIH HHS R21 AI151362
6 · The paper itself

Abstract

Carbapenemase-producing

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesEnterobacter cloacaeKlebsiella pneumoniaeMicrobial Sensitivity TestsAdultAgedAged, 80 and overAztreonamDrug Resistance, Multiple, BacterialEnterobacteriaceae InfectionsFemaleHumansJapanKlebsiella InfectionsAnti-Bacterial AgentsAztreonamBacterial Proteinsbeta-Lactamasescarbapenemasecarbapenemase-producing Enterobacteralesclinical outcomegenome epidemiologymetallo-beta-lactamase

Identifiers

PMID38517188
PMCPMC11064536
OpenAlexW4393097008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.